Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | BRAF | P15056 | 2/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.69 |
| ▸ | STK17B | O94768 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25341847 | 1.00 | EGFR (0.72) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL30879224 | 0.89 | EGFR (0.75) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL4220279 | 0.89 | EGFR (0.75) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL30213428 | 0.89 | EGFR (0.75) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL4226041 | 0.87 | EGFR (0.81) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL25599836 | 0.86 | EGFR (0.76) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL24637154 | 0.85 | EGFR (0.83) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL17557967 | 0.85 | EGFR (0.75) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL22338480 | 0.85 | EGFR (0.92) | EGFRERBB2KDRBRAFCIT | |
| SCHEMBL25599785 | 0.85 | EGFR (0.77) | EGFRERBB2KDRBRAFCIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129088-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | CRBN, UBE3A, UBE3C | EGFR 1635/4885ERBB2 2268/4885KDR 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.